JP2019081811A5 - - Google Patents

Download PDF

Info

Publication number: JP2019081811A5
Authority: JP; Japan
Prior art keywords: component; liquid pharmaceutical; sodium; pharmaceutical formulation; acetate
Prior art date: 2019-03-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2019040987A

Other languages

English (en)

Japanese (ja)

Other versions

JP6826140B2 (ja

JP2019081811A (ja

Filing date

2019-03-06

Publication date

2019-11-14

2019-03-06 Application filed filed Critical

2019-05-30 Publication of JP2019081811A publication Critical patent/JP2019081811A/ja

2019-11-14 Publication of JP2019081811A5 publication Critical patent/JP2019081811A5/ja

2021-02-03 Application granted granted Critical

2021-02-03 Publication of JP6826140B2 publication Critical patent/JP6826140B2/ja

Status Active legal-status Critical Current

2038-09-20 Anticipated expiration legal-status Critical

Links

239000007788 liquid Substances 0.000 claims 5
239000008194 pharmaceutical composition Substances 0.000 claims 4
150000003839 salts Chemical class 0.000 claims 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
108010049264 Teriparatide Proteins 0.000 claims 2
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
239000011575 calcium Substances 0.000 claims 1
229910052791 calcium Inorganic materials 0.000 claims 1
239000001110 calcium chloride Substances 0.000 claims 1
229910001628 calcium chloride Inorganic materials 0.000 claims 1
238000006243 chemical reaction Methods 0.000 claims 1
229910001629 magnesium chloride Inorganic materials 0.000 claims 1
159000000003 magnesium salts Chemical class 0.000 claims 1
BUUKFBVDKSFMHN-LKMAISLMSA-N parathar acetate Chemical compound CC(O)=O.C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 BUUKFBVDKSFMHN-LKMAISLMSA-N 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
239000001632 sodium acetate Substances 0.000 claims 1
235000017281 sodium acetate Nutrition 0.000 claims 1
229910000029 sodium carbonate Inorganic materials 0.000 claims 1
239000011780 sodium chloride Substances 0.000 claims 1
239000001509 sodium citrate Substances 0.000 claims 1
238000007920 subcutaneous administration Methods 0.000 claims 1
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 1
229960005460 teriparatide Drugs 0.000 claims 1
229960000338 teriparatide acetate Drugs 0.000 claims 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
229940038773 trisodium citrate Drugs 0.000 claims 1

JP2019040987A 2017-09-22 2019-03-06 安定性に優れるテリパラチド含有液状医薬組成物 Active JP6826140B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2017182611		2017-09-22
JP2017182611		2017-09-22

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018558440A Division JP6577683B2 (ja)	2017-09-22	2018-09-20	安定性に優れるテリパラチド含有液状医薬組成物

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2020201121A Division JP6851536B2 (ja)	2017-09-22	2020-12-03	安定性に優れるテリパラチド含有液状医薬組成物

Publications (3)

Publication Number	Publication Date
JP2019081811A JP2019081811A (ja)	2019-05-30
JP2019081811A5 true JP2019081811A5 (2)	2019-11-14
JP6826140B2 JP6826140B2 (ja)	2021-02-03

Family

ID=65811407

Family Applications (17)

Application Number	Title	Priority Date	Filing Date
JP2018558440A Active JP6577683B2 (ja)	2017-09-22	2018-09-20	安定性に優れるテリパラチド含有液状医薬組成物
JP2019008797A Active JP6714738B2 (ja)	2017-09-22	2019-01-22	安定性に優れるテリパラチド含有液状医薬組成物
JP2019008790A Active JP6585317B2 (ja)	2017-09-22	2019-01-22	安定性に優れるテリパラチド含有液状医薬組成物
JP2019040987A Active JP6826140B2 (ja)	2017-09-22	2019-03-06	安定性に優れるテリパラチド含有液状医薬組成物
JP2019041011A Active JP6817358B2 (ja)	2017-09-22	2019-03-06	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057412A Active JP6781790B2 (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057434A Active JP6646173B2 (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057398A Active JP6581741B2 (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057408A Active JP6634175B2 (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057438A Pending JP2019089865A (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019085817A Active JP6825034B2 (ja)	2017-09-22	2019-04-26	安定性に優れるテリパラチド含有液状医薬組成物
JP2019228968A Active JP6739612B2 (ja)	2017-09-22	2019-12-19	安定性に優れるテリパラチド含有液状医薬組成物
JP2020053255A Active JP6766286B2 (ja)	2017-09-22	2020-03-24	安定性に優れるテリパラチド含有液状医薬組成物
JP2020139570A Active JP6818928B2 (ja)	2017-09-22	2020-08-20	安定性に優れるテリパラチド含有液状医薬組成物
JP2020201121A Active JP6851536B2 (ja)	2017-09-22	2020-12-03	安定性に優れるテリパラチド含有液状医薬組成物
JP2020218741A Active JP6977137B2 (ja)	2017-09-22	2020-12-28	安定性に優れるテリパラチド含有液状医薬組成物
JP2021036829A Pending JP2021088606A (ja)	2017-09-22	2021-03-09	安定性に優れるテリパラチド含有液状医薬組成物

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
JP2018558440A Active JP6577683B2 (ja)	2017-09-22	2018-09-20	安定性に優れるテリパラチド含有液状医薬組成物
JP2019008797A Active JP6714738B2 (ja)	2017-09-22	2019-01-22	安定性に優れるテリパラチド含有液状医薬組成物
JP2019008790A Active JP6585317B2 (ja)	2017-09-22	2019-01-22	安定性に優れるテリパラチド含有液状医薬組成物

Family Applications After (13)

Application Number	Title	Priority Date	Filing Date
JP2019041011A Active JP6817358B2 (ja)	2017-09-22	2019-03-06	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057412A Active JP6781790B2 (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057434A Active JP6646173B2 (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057398A Active JP6581741B2 (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057408A Active JP6634175B2 (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019057438A Pending JP2019089865A (ja)	2017-09-22	2019-03-25	安定性に優れるテリパラチド含有液状医薬組成物
JP2019085817A Active JP6825034B2 (ja)	2017-09-22	2019-04-26	安定性に優れるテリパラチド含有液状医薬組成物
JP2019228968A Active JP6739612B2 (ja)	2017-09-22	2019-12-19	安定性に優れるテリパラチド含有液状医薬組成物
JP2020053255A Active JP6766286B2 (ja)	2017-09-22	2020-03-24	安定性に優れるテリパラチド含有液状医薬組成物
JP2020139570A Active JP6818928B2 (ja)	2017-09-22	2020-08-20	安定性に優れるテリパラチド含有液状医薬組成物
JP2020201121A Active JP6851536B2 (ja)	2017-09-22	2020-12-03	安定性に優れるテリパラチド含有液状医薬組成物
JP2020218741A Active JP6977137B2 (ja)	2017-09-22	2020-12-28	安定性に優れるテリパラチド含有液状医薬組成物
JP2021036829A Pending JP2021088606A (ja)	2017-09-22	2021-03-09	安定性に優れるテリパラチド含有液状医薬組成物

Country Status (6)

Country	Link
US (2)	US20200289621A1 (2)
EP (1)	EP3685849A4 (2)
JP (17)	JP6577683B2 (2)
CN (2)	CN116898955A (2)
CA (1)	CA3075977C (2)
WO (1)	WO2019059302A1 (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20200289621A1 (en) *	2017-09-22	2020-09-17	Asahi Kasei Pharma Corporation	Teriparatide-containing liquid pharmaceutical composition having excellent stability
ES3009869T3 (en) *	2018-10-29	2025-03-31	Asahi Kasei Pharma Corp	An improved teriparatide dosage regimen for use in preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
WO2021044775A1 (ja) *	2019-09-05	2021-03-11	旭化成ファーマ株式会社	テリパラチド又はその塩を含有する無菌注射剤を製造する方法
JP6965474B1 (ja) *	2019-12-09	2021-11-10	旭化成ファーマ株式会社	テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法
KR102570011B1 (ko) *	2019-12-18	2023-08-23	주식회사 대웅제약	1-(5-(2,4-다이플루오로페닐)-1-((3-플루우로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 액상 약학적 조성물
WO2021229835A1 (ja) *	2020-05-11	2021-11-18	旭化成ファーマ株式会社	テリパラチド又はその塩を含有する安定な液状医薬製剤
CN114306249A (zh) *	2020-09-28	2022-04-12	深圳翰宇药业股份有限公司	一种特立帕肽冻干药物组合物及其制备方法
CN114031680B (zh) *	2021-09-01	2024-03-26	浙江湃肽生物有限公司	一种索玛鲁肽钠盐及其制备方法与应用
CN114316021A (zh) *	2021-12-29	2022-04-12	江苏诺泰澳赛诺生物制药股份有限公司	一种特立帕肽及的纯化方法
WO2025032376A1 (en) *	2023-08-04	2025-02-13	Precise Biopharma Pvt Ltd	A room temperature stable solution for injection of abaloparatide

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6357527A (ja)	1986-08-28	1988-03-12	Toyo Jozo Co Ltd	薬剤の吸着防止方法
JPH0669956B2 (ja)	1988-09-30	1994-09-07	旭化成工業株式会社	ポリペプタイド類の吸着防止剤
NL9001681A (nl) *	1990-07-24	1992-02-17	Rijksuniversiteit	Transmucosale geneesmiddelpreparaten en transmucosale toediening.
JP2662842B2 (ja) *	1991-12-09	1997-10-15	旭化成工業株式会社	パラサイロイドホルモンの安定化組成物
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
JPH11292787A (ja) *	1995-08-15	1999-10-26	Asahi Chem Ind Co Ltd	生理活性ペプチドを含有する経粘膜投与製剤
DE19538687A1 (de) *	1995-10-17	1997-04-24	Boehringer Mannheim Gmbh	Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
ZA9811127B (en) *	1997-12-09	2000-07-11	Lilly Co Eli	Stabilized teriparatide solutions.
JPH11235390A (ja) *	1997-12-12	1999-08-31	Takeda Chem Ind Ltd	経皮透過方法
PL341209A1 (en) *	1997-12-18	2001-03-26	Lilly Co Eli	Crystalline teriparatide
SE9801495D0 (sv) *	1998-04-28	1998-04-28	Astra Ab	Protein formulationa
DZ2873A1 (fr) *	1998-08-19	2003-12-15	Lilly Co Eli	Procédé pour augmenter la dureté et la rigidité osseuse.
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
US20020061838A1 (en) *	2000-05-17	2002-05-23	Barton Holmquist	Peptide pharmaceutical formulations
IL147731A0 (en)	2000-05-19	2002-08-14	Bionebraska Inc	Peptide pharmaceutical formulations
KR100782606B1 (ko) *	2000-10-09	2007-12-06	일라이 릴리 앤드 캄파니	부갑상선 호르몬 투약을 위한 펜 장치
DE10116552A1 (de) *	2001-04-03	2002-10-10	Abc Armbruster Biochemicals	Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
JP5052736B2 (ja) *	2001-05-30	2012-10-17	中外製薬株式会社	タンパク質製剤
US6896894B2 (en) *	2001-10-30	2005-05-24	Battelle Memorial Institute	Proteins stabilized with polysaccharide gums
EP1444263A4 (en) *	2001-11-05	2005-04-20	Lilly Co Eli	METHOD FOR IMPROVING THE STABILITY OF A BONE BINDING IMPLANT
JP4252260B2 (ja) *	2002-06-05	2009-04-08	旭化成ファーマ株式会社	Ｐｔｈの安定化水溶液注射剤
KR101235507B1 (ko) *	2003-02-28	2013-02-20	추가이 세이야쿠 가부시키가이샤	단백질을 함유하는 안정화 제제
WO2005014034A1 (en) *	2003-07-14	2005-02-17	Nps Allelix Corp.	Stabilized formulation of parathyroid hormone
JP4707327B2 (ja)	2004-01-27	2011-06-22	旭化成ファーマ株式会社	ポリペプタイド類の吸着防止剤
CA2567056A1 (en) *	2004-05-10	2005-12-08	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7556821B2 (en) *	2004-05-13	2009-07-07	Alza Corporation	Apparatus and method for transdermal delivery of parathyroid hormone agents
CN100566669C (zh) *	2004-05-13	2009-12-09	阿尔扎公司	甲状旁腺激素药物的透皮释放装置
KR101149454B1 (ko) *	2004-08-24	2012-05-25	간가와 겐지	생리활성 펩티드의 액상 제제
KR100700869B1 (ko) *	2005-06-03	2007-03-29	재단법인 목암생명공학연구소	Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
US20110046059A1 (en) *	2005-09-06	2011-02-24	Zelos Therapeutics, Inc.	Pharmaceutically acceptable formulations/compositions for peptidyl drugs
KR20080059430A (ko) *	2005-10-06	2008-06-27	나스텍 파마수티컬 컴퍼니 인코포레이티드	부갑상선 호르몬 제형 및 그 사용 방법
WO2007044375A2 (en) *	2005-10-06	2007-04-19	Nastech Pharmaceutical Company Inc.	Pth formulations and methods of use
JP5522879B2 (ja)	2006-01-16	2014-06-18	旭化成ファーマ株式会社	樹脂容器中の生理活性ペプチドの安定性改善方法
CA2659846A1 (en) *	2006-07-31	2008-02-07	Zelos Therapeutics, Inc.	Parathyroid hormone analogues and methods of use
CA2930681C (en) *	2007-04-09	2019-10-15	The Board Of Trustees Of The University Of Arkansas	Fusion protein of collagen-binding domain and parathyroid hormone
DE602008004351D1 (de) *	2007-06-29	2011-02-17	Atrm Llc	Flüssige proteinformulierungen mit gdf-5 zur verwendung bei erhöhten temperaturen
EP2052736A1 (en) *	2007-10-26	2009-04-29	Nycomed Danmark ApS	Parathyroid hormone formulations und uses thereof
BRPI0911048A2 (pt) *	2008-04-14	2015-12-29	Atrm Llc	formulações líquidas tamponadas de gdf-5
CN103599541A (zh) *	2008-09-10	2014-02-26	弗·哈夫曼-拉罗切有限公司	用于防止蛋白质氧化降解的组合物和方法
AU2015201581B2 (en) *	2008-09-17	2017-03-09	Amryt Endo, Inc.	Pharmaceutical Compositions and Related Methods of Delivery
CN102281901A (zh) *	2008-11-20	2011-12-14	弗·哈夫曼-拉罗切有限公司	治疗性蛋白质制剂
JP2009091363A (ja) *	2008-11-21	2009-04-30	Asahi Kasei Pharma Kk	Ｐｔｈの安定化水溶液注射剤
US8481678B2 (en)	2009-03-30	2013-07-09	E I Du Pont De Nemours And Company	Peptide-based tooth whitening reagents
WO2011011675A1 (en) *	2009-07-23	2011-01-27	Zelos Therapeutics, Inc.	Pharmaceutically acceptable formulations/compositions for peptidyl drugs
KR20190095552A (ko) *	2009-09-09	2019-08-14	아사히 가세이 파마 가부시키가이샤	1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
WO2011139838A2 (en)	2010-04-28	2011-11-10	Zelos Therapeutics, Inc.	Intranasal formulations
WO2012075375A1 (en) *	2010-12-02	2012-06-07	Lanco Biosciences, Inc.	Delivery of parathyroid hormones by microinjection systems
AU2012225268B2 (en)	2011-03-10	2016-10-20	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of peptide drugs
KR20150116467A (ko)	2011-06-07	2015-10-15	아사히 가세이 파마 가부시키가이샤	고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
WO2013063277A1 (en) *	2011-10-25	2013-05-02	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP2015504087A (ja) *	2012-01-20	2015-02-05	ルピン・リミテッドＬｕｐｉｎＬｉｍｉｔｅｄ	安定化ｐｔｈ製剤
AU2013247645B2 (en) *	2012-04-09	2019-02-14	Daiichi Sankyo Company, Limited	Anti-FGFR2 antibody
CN103301058A (zh) *	2013-06-17	2013-09-18	深圳翰宇药业股份有限公司	一种特立帕肽注射用组合物及其制备方法和制剂
WO2016065181A1 (en) *	2014-10-23	2016-04-28	Amgen Inc.	Reducing viscosity of pharmaceutical formulations
CN108025042A (zh) *	2015-07-06	2018-05-11	董正欣	PTHrP类似物的新型制剂
JP6634758B2 (ja) *	2015-09-25	2020-01-22	ニプロ株式会社	液体組成物及び凍結乾燥製剤
JP6641870B2 (ja) *	2015-10-14	2020-02-05	ニプロ株式会社	パラサイロイドホルモン類含有製剤の製造方法
JP2018188399A (ja) *	2017-05-10	2018-11-29	ニプロ株式会社	テリパラチドのプレフィルドシリンジ製剤
US20200289621A1 (en) *	2017-09-22	2020-09-17	Asahi Kasei Pharma Corporation	Teriparatide-containing liquid pharmaceutical composition having excellent stability

2018
- 2018-09-20 US US16/649,254 patent/US20200289621A1/en not_active Abandoned
- 2018-09-20 CN CN202311111773.2A patent/CN116898955A/zh active Pending
- 2018-09-20 CA CA3075977A patent/CA3075977C/en active Active
- 2018-09-20 EP EP18859204.2A patent/EP3685849A4/en not_active Withdrawn
- 2018-09-20 JP JP2018558440A patent/JP6577683B2/ja active Active
- 2018-09-20 WO PCT/JP2018/034887 patent/WO2019059302A1/ja not_active Ceased
- 2018-09-20 CN CN201880053788.9A patent/CN110996988A/zh active Pending
2019
- 2019-01-22 JP JP2019008797A patent/JP6714738B2/ja active Active
- 2019-01-22 JP JP2019008790A patent/JP6585317B2/ja active Active
- 2019-03-06 JP JP2019040987A patent/JP6826140B2/ja active Active
- 2019-03-06 JP JP2019041011A patent/JP6817358B2/ja active Active
- 2019-03-25 JP JP2019057412A patent/JP6781790B2/ja active Active
- 2019-03-25 JP JP2019057434A patent/JP6646173B2/ja active Active
- 2019-03-25 JP JP2019057398A patent/JP6581741B2/ja active Active
- 2019-03-25 JP JP2019057408A patent/JP6634175B2/ja active Active
- 2019-03-25 JP JP2019057438A patent/JP2019089865A/ja active Pending
- 2019-04-26 JP JP2019085817A patent/JP6825034B2/ja active Active
- 2019-12-19 JP JP2019228968A patent/JP6739612B2/ja active Active
2020
- 2020-03-24 JP JP2020053255A patent/JP6766286B2/ja active Active
- 2020-08-20 JP JP2020139570A patent/JP6818928B2/ja active Active
- 2020-12-03 JP JP2020201121A patent/JP6851536B2/ja active Active
- 2020-12-28 JP JP2020218741A patent/JP6977137B2/ja active Active
2021
- 2021-03-09 JP JP2021036829A patent/JP2021088606A/ja active Pending
- 2021-03-19 US US17/206,987 patent/US20210205418A1/en active Pending

Publication	Publication Date	Title
JP2019081811A5 (2)	2019-11-14
JP2019131596A5 (2)	2019-10-17
JP2018021007A5 (2)	2019-08-22
JP2015527402A5 (2)	2016-10-27
AR098013A2 (es)	2016-04-27	UNA COMPOSICIÓN FARMACÉUTICA ACUOSA ESTÉRIL, LISTA PARA SU USO, ADECUADA PARA LA ADMINISTRACIÓN PARENTERAL, MEDIANTE INFUSIÓN PARA EL TRATAMIENTO DE CONDICIONES CARDÍACAS, ENVASADA EN UN RECIPIENTE SELLADO, Y QUE POSEE UN pH ENTRE 3,5 Y 6,5, Y MÉTODO PARA SU FABRICACIÓN
JP2008526757A5 (2)	2009-02-12
JP2010529999A5 (2)	2011-07-28
JP2019536761A5 (2)	2020-08-20
JP2014520852A5 (2)	2015-09-03
JP2016512210A5 (2)	2017-06-01
JP2017531033A5 (2)	2017-11-30
JP2011105739A5 (2)	2012-04-12
JP2016512833A (ja)	2016-05-09	ウイルス感染症の治療薬としてのベラプロスト異性体
JP2009521269A5 (2)	2010-02-18
JP2017533930A5 (2)	2019-04-25
JP2019533713A5 (2)	2020-12-17
JP2017002035A5 (2)	2019-07-04
JP2016515623A5 (2)	2017-05-18
JP2018039810A5 (2)	2018-05-17
JP2015509514A5 (2)	2016-05-19
JP2005068010A5 (2)	2005-06-16
JP2011516544A5 (2)	2013-08-01
JP2022514597A5 (2)	2022-12-21
JPH04297417A (ja)	1992-10-21	治療システム
JP2016512493A5 (2)	2017-04-20